3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
7
Multiple Myeloma
6
Neoplasms
5
Burkitt Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Ovarian Neoplasms
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma
4
Lymphoma, Non-Hodgkin
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Waldenstrom Macroglobulinemia
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
Melanoma
2
Medulloblastoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Large Granular Lymphocytic
2
Intraocular Lymphoma
2
Interventions
toripalimab
1
fludarabine
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Epstein-Barr Virus Infections
×
Cyclophosphamide
×
Clear all
NCT06224049
2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1
Recruiting
6 enrolled